TSX:IN
OTCQX:IMLFF
VANCOUVER, BC, May 8, 2019 /CNW/ - InMed Pharmaceuticals
Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a
biopharmaceutical company developing a proprietary biosynthesis
platform technology for the manufacturing of pharmaceutical-grade
cannabinoids as well as an R&D pipeline of medications
targeting diseases with high unmet medical needs, will report
financial results for the three months ended March 31, 2019, which is the Company's third
quarter of fiscal year 2019 ("3Q19"), on Wednesday, May 15, 2019.
Conference Call
& Webcast:
|
Wednesday, May 15,
2019 at 10:00 AM Pacific Time, 1:00 PM Eastern Time
|
Toronto:
|
+1.416.764.8688
|
Vancouver:
|
+1.778.383.7413
|
North America (Toll
Free):
|
+1.888.390.0546
|
Conference
ID:
|
17193517
|
Webcast:
https://event.on24.com/wcc/r/1999675/955779A89027D040E64A5A3804E51DBE
|
Replays,
Available through May 22, 2019:
|
Toronto:
|
+1.416.764.8677
|
North America (Toll
Free):
|
+1.888.390.0541
|
Playback
Passcode:
|
193517 #
|
The Company's full financial statements and related MD&A for
the three months ended March 31, 2019
will be available at www.sedar.com on May
15, 2019.
About InMed:
InMed Pharmaceuticals is a
biopharmaceutical company developing a proprietary biosynthesis
system for the manufacturing of pharmaceutical-grade cannabinoids,
as well as a pipeline of cannabinoid-based medications that target
diseases with high unmet medical needs. The Company is
dedicated to delivering new therapeutic alternatives to patients
that may benefit from cannabinoid-based medicines. For more
information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: reporting 3Q19 financial results on
May 15, 2019; the manufacturing of
pharmaceutical-grade cannabinoids; and the development of
medications targeting diseases with high unmet medical needs.
With respect to the forward-looking information contained in
this news release, InMed has made numerous assumptions regarding,
among other things: continued and timely positive preclinical and
clinical efficacy data; the speed of regulatory approvals; demand
for InMed's products; and continued economic and market
stability. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk factors which
could cause InMed's actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
information contained herein. Known risk factors include,
among others: financial results may not be reported on the
anticipated date; preclinical and clinical testing may not produce
the desired results on a timely basis, or at all; regulatory
applications may not be approved on a timely basis, or at all;
suitable partners may not be located; economic or market conditions
may worsen; InMed may be unable to manufacture pharmaceutical-grade
cannabinoids on a timely basis, or at all; and InMed may be unable
to develop medications targeting diseases with high unmet medical
needs on a timely basis, or at all. A more complete
discussion of the risks and uncertainties facing InMed is disclosed
in InMed's most recent Annual Information Form and other continuous
disclosure filed with Canadian securities regulatory authorities on
SEDAR at www.sedar.com.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO
STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/inmed-pharmaceuticals-to-report-third-quarter-fiscal-2019-financial-results-and-business-update-on-may-15-2019-300845506.html
SOURCE InMed Pharmaceuticals Inc.